- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:06 | Psyence Biomedical Ltd.: Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine | 149 | GlobeNewswire (Europe) | HIGHLIGHTS Texas Ibogaine Research Corporation ("TIRC"), the wholly-owned Texas subsidiary of Psyence BioMed, enters manufacturing partnership with Benuvia Operations, LLC for the planned U.S. manufacture... ► Artikel lesen | |
| 13:00 | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 28.09. | Psyence BioMed unit signs term sheet for U.S. ibogaine rights | 2 | Investing.com | ||
| 28.09. | Psyence Biomedical Ltd.: Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation | 307 | GlobeNewswire (Europe) | NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research... ► Artikel lesen | |
| 23.09. | Psyence BioMed investiert bis zu 5 Mio. USD in PsyLabs und plant Ibogain-Studie | 2 | Investing.com Deutsch | ||
| 23.09. | Psyence Biomedical Ltd.: Psyence BioMed Announces Strategic Ibogaine Investment | 391 | GlobeNewswire (Europe) | Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential... ► Artikel lesen | |
| 23.09. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 14.09. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.09. | Psyence Biomedical Ltd.: Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development | 299 | GlobeNewswire (Europe) | HIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine developmentPositioned to hold U.S. rights to PsyLabs' pharmaceutical-grade ibogaine, subject to completion... ► Artikel lesen | |
| 08.09. | Eli Lilly, AbbVie und Johnson & Johnson: Wie der Fünf-Milliarden-Dollar-Pharma-Run auf Psychedelika Emyria in den Fokus rückt | Small- & Micro Cap Investment | |||
| 18.08. | Psyence BioMed responds to Trump ibogaine announcement | 2 | Investing.com | ||
| 18.08. | Psyence BioMed positioniert sich nach Trump-Ankündigung zu Ibogain | 12 | Investing.com Deutsch | ||
| 18.08. | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development | 289 | GlobeNewswire (Europe) | NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company focused on the development and supply of nature-derived... ► Artikel lesen | |
| 18.08. | Trump-Ankündigung zu Ibogain lässt Aktie von Psyence Biomedical haussieren | 2 | Investing.com Deutsch | ||
| 06.08. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 22.06. | PSYENCE BIOMEDICAL LTD. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 05.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.05. | Psyence Biomedical Ltd.: Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing | 1 | GlobeNewswire (USA) | ||
| 23.04. | Psyence Biomedical doses first patient in psilocybin cancer trial | 2 | Investing.com | ||
| 23.04. | Psyence Biomedical startet Phase-IIb-Studie mit Psilocybin bei Krebspatienten | 2 | Investing.com Deutsch |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,587 | +1,93 % | TOP-MELDUNG bei Valneva: Meine brandneue Prognose ändert einfach alles - Dringend handeln! | ||
| BIOFRONTERA | 3,490 | +1,16 % | PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Biofrontera... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,330 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,925 | +1,54 % | H.C. Wainwright raises Ocugen stock price target on Bahamas approval | ||
| DEFENCE THERAPEUTICS | 0,237 | -1,66 % | Defence Therapeutics Inc.: Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates | Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,080 | -2,26 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,520 | -0,13 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,270 | +0,80 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| IMMUNITYBIO | 9,440 | +3,28 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,500 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| IMMATICS | 6,750 | +0,15 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| TRAWS PHARMA | 0,561 | 0,00 % | Traws Pharma Ties Up To $50 Million Of Additional Financing To Influenza Regulatory And Clinical Milestones | ||
| OCULAR THERAPEUTIX | 6,250 | +0,81 % | RBC Capital bestätigt Rating für Ocular Therapeutix und sieht Potenzial in AMD-Therapie | ||
| VERASTEM | 6,954 | +1,61 % | Verastem shares get Buy rating reiterated by H.C. Wainwright | ||
| CURIS | 0,797 | +10,71 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen |
Das Unternehmen PSYENCE BIOMEDICAL LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,180 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.